Paula Rodríguez‐Otero, Surbhi Sidana, Mathilde C.M. Kouwenhoven, Jordan M. Schecter, Nikoletta Lendvai, Kevin C. De Braganca, Ana Slaughter, Carolina Lonardi, Philip Vlummens, Helen Varsos, Christina Corsale, Deepu Madduri, Hao Zhao, Katherine Li, Erin Lee, Loreta Marquez, Man Zhao, Tzu‐Min Yeh, Diana Chen, Vicki Plaks, Rocío Montes de, Erika Florendo, Nitin Patel, Muhammad Akram, Mythili Koneru, Bianca Santomasso, Jaime Gállego Pérez‐Larraya, Niels W.C.J. van de Donk
Ciltacabtagene autoleucel (cilta-cel), an approved B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, showed strong efficacy in heavily pre-treated patients with RRMM and in patients at earlier lines of therapy (LOT) in the single-arm CARTITUDE-1, multi-cohort CARTITUDE-2, and phase 3 CARTITUDE-4 trials [ 1 , 2 , 3 , 4 , 5 , 6 ]. The cilta-cel adverse event (AE) profile was consistent with that of the CAR-T class, which includes immune-related toxicities like cytokine release syndrome (CRS) and neurologic events like immune effector cell–associated neurotoxicity syndrome (ICANS) [ 6 , 7 ]. Reports of cranial nerve (CN) palsy (CNP) following CAR T-cell therapy are infrequent [ 2 , 8 , 9 , 10 , 11 , 12 ], and guidance on its management is needed. We describe clinical experience with CNP presentation and management after cilta-cel in CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4.